Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates

Protagonist Therapeutics (PTGX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.08%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.53 per share when it actually produced a loss of $0.55, delivering a surprise of -3.77%.Over the last four quart ...